cyc 202 has been researched along with abt-737 in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (abt-737) | Trials (abt-737) | Recent Studies (post-2010) (abt-737) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 632 | 0 | 484 |
| Protein | Taxonomy | cyc 202 (IC50) | abt-737 (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.002 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0206 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.02 | |
| BH3-interacting domain death agonist | Homo sapiens (human) | 0.0485 | |
| Apoptosis regulator BAX | Homo sapiens (human) | 0.023 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0207 | |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | 0.0248 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 3.44 | |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | 0.0335 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.0335 | |
| Bcl-2-binding component 3, isoforms 1/2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fesik, SW; Huang, X; Li, L; Lin, X; Morgan-Lappe, S; Shen, Y; Vernetti, LA; Zakula, DM | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Harada, H | 1 |
2 other study(ies) available for cyc 202 and abt-737
| Article | Year |
|---|---|
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Blotting, Western; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; RNA Interference; RNA, Small Interfering; Roscovitine; Sorafenib; Sulfonamides; Transmembrane Activator and CAML Interactor Protein; Zinc Fingers | 2007 |
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Biphenyl Compounds; Cyclin-Dependent Kinases; Down-Regulation; Drug Synergism; HL-60 Cells; Humans; Jurkat Cells; Leukemia; Mice; Mice, Knockout; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; RNA Interference; Roscovitine; Sulfonamides; U937 Cells | 2007 |